Charles River Laboratories International’s (CRL) “Buy” Rating Reaffirmed at SunTrust Banks, Inc.

SunTrust Banks, Inc. reissued their buy rating on shares of Charles River Laboratories International, Inc. (NYSE:CRL) in a report issued on Friday. They currently have a $113.00 price target on the medical research company’s stock. SunTrust Banks also issued estimates for Charles River Laboratories International’s Q4 2017 earnings at $1.26 EPS, FY2017 earnings at $5.15 EPS, FY2018 earnings at $5.68 EPS and FY2019 earnings at $6.47 EPS.

CRL has been the subject of several other reports. Zacks Investment Research downgraded Charles River Laboratories International from a buy rating to a hold rating in a research note on Friday, August 11th. Robert W. Baird set a $117.00 target price on Charles River Laboratories International and gave the stock a buy rating in a research note on Monday, November 13th. Bank of America Corporation reduced their target price on Charles River Laboratories International from $117.00 to $115.00 and set a buy rating for the company in a research note on Friday, November 10th. BidaskClub raised Charles River Laboratories International from a buy rating to a strong-buy rating in a research note on Tuesday, August 22nd. Finally, Jefferies Group LLC upped their target price on Charles River Laboratories International from $120.00 to $130.00 and gave the stock a buy rating in a research note on Monday, October 9th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $106.63.

Charles River Laboratories International (CRL) opened at $101.51 on Friday. Charles River Laboratories International has a twelve month low of $69.51 and a twelve month high of $119.05. The stock has a market capitalization of $4,800.00, a P/E ratio of 19.92, a price-to-earnings-growth ratio of 1.62 and a beta of 0.94. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The company had revenue of $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. During the same period in the previous year, the company posted $1.18 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 9.0% on a year-over-year basis. equities research analysts predict that Charles River Laboratories International will post 5.13 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/21/charles-river-laboratories-internationals-crl-buy-rating-reaffirmed-at-suntrust-banks-inc.html.

In related news, insider Davide Molho sold 6,165 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Over the last three months, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. 2.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 0.5% in the 2nd quarter. Vanguard Group Inc. now owns 5,060,730 shares of the medical research company’s stock valued at $511,893,000 after buying an additional 27,217 shares in the last quarter. BlackRock Inc. grew its holdings in Charles River Laboratories International by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,022,882 shares of the medical research company’s stock valued at $406,913,000 after buying an additional 177,239 shares in the last quarter. FMR LLC grew its holdings in Charles River Laboratories International by 23.8% in the 2nd quarter. FMR LLC now owns 3,079,179 shares of the medical research company’s stock valued at $311,458,000 after buying an additional 591,066 shares in the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.3% in the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after buying an additional 28,365 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Charles River Laboratories International by 14.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,219,883 shares of the medical research company’s stock valued at $123,391,000 after buying an additional 153,374 shares in the last quarter. Institutional investors own 98.72% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply